AMNEAL PHARMACEUTICALS INC (AMRX) Stock News

USA - NASDAQ:AMRX - US03168L1052 - Common Stock

10.455 USD

+0.17 (+1.6%)

Last: 10/22/2025, 11:40:57 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AMRX Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Benzinga - Mentions: AMPH TEVA RDY VTRS

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

16 days ago - By: Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma - Mentions: ALVO

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

3 months ago - By: Benzinga - Mentions: AFG CXDO YUM PACK ...

Earnings Scheduled For August 5, 2025

20 days ago - By: Zacks Investment Research - Mentions: ANIX

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

22 days ago - By: Amneal Pharmaceuticals LLC

Amneal to Report Third Quarter 2025 Results on October 30, 2025

22 days ago - By: Amneal Pharmaceuticals LLC

Amneal to Report Third Quarter 2025 Results on October 30, 2025

a month ago - By: Amneal Pharmaceuticals LLC

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

a month ago - By: Amneal Pharmaceuticals LLC

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

a month ago - By: Stocktwits - Mentions: AGN

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops

a month ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

a month ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

a month ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

2 months ago - By: Zacks Investment Research

Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet

2 months ago - By: Zacks Investment Research

Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?

2 months ago - By: Zacks Investment Research - Mentions: BSX

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

2 months ago - By: Zacks Investment Research

Here's Why Momentum in Amneal (AMRX) Should Keep going

3 months ago - By: The Motley Fool

Amneal (AMRX) Q2 EPS Jumps 56%

3 months ago - By: Zacks Investment Research

Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

3 months ago - By: Zacks Investment Research - Mentions: CATX

Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates

3 months ago - By: Amneal Pharmaceuticals LLC

Amneal Reports Second Quarter 2025 Financial Results

3 months ago - By: Amneal Pharmaceuticals LLC

Amneal Reports Second Quarter 2025 Financial Results

3 months ago - By: Zacks Investment Research - Mentions: PFE EXAS VTRS

Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?

3 months ago - By: Zacks Investment Research - Mentions: LLY NKTR CRMD

Nektar Gears Up to Report Q2 Earnings: What's in the Cards?

3 months ago - By: Zacks Investment Research - Mentions: TECH CRMD GMAB

Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?